Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).

@article{Culine2007RefiningTO,
  title={Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).},
  author={St{\'e}phane Culine and Pierre Kerbrat and Andrew Kramar and Christine A Theodore and Christine Chevreau and Lionnel Geoffrois and Nguyen Bui and Jean P{\'e}ny and Armelle Caty and R{\'e}my Delva and Pierre Biron and Karim S Fizazi and Jeannine Bouzy and J. P. Droz},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2007},
  volume={18 5},
  pages={917-24}
}
BACKGROUND High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin. PATIENTS AND METHODS Patients received either three cycles of BE500P or four cycles of E500P every 3 weeks. Disease was defined according to the Institut Gustave Roussy prognostic model. Patients were retrospectively assigned into the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. A sample size of 250 patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…